Home > Insider Trading > Merck Sharp & Dohme Corp. > Profile

Merck Sharp & Dohme Corp. (MRK)

Market is closed

Get Email Alerts

Profile
Hedge Fund Holdings
Insider Purchases
Insider Sales
Institutional Holdings
13 D/G Filings
News

Get Email Alerts

Sector: Pharmaceutical Preparations

Related Insiders

E Carlos Represas, Director, 2011-01-20
T Richard Clark, Officer, Director, 2009-11-04
S Peter Kim, Officer, 2009-11-04

E Carlos Represas, Director, 2011-01-20
T Richard Clark, Officer, Director, 2009-11-04
S Peter Kim, Officer, 2009-11-04
A Celia Colbert, Officer, 2009-11-04
John Canan, Officer, 2009-11-04
C Kenneth Frazier, Officer, 2009-11-04
N Bruce Kuhlik, Officer, 2009-11-04
Stefan Oschmann, Officer, 2009-11-04
A Willie Deese, Officer, 2009-11-04
M Mirian Weir Graddick, Officer, 2009-11-04
Chris J Scalet, Officer, 2009-11-04
E Mark Mcdonough, Officer, 2009-11-04
H Adam Schechter, Officer, 2009-11-04
P Wendell Weeks, Director, 2009-11-04
C Peter Wendell, Director, 2009-11-04
Md O Samuel Thier, Director, 2009-11-04
M Anne Tatlock, Director, 2009-11-04
E Thomas Shenk, Director, 2009-11-04
B Rochelle Lazarus, Director, 2009-11-04
N Willam Kelley, Director, 2009-11-04
R Harry Jacobson, Director, 2009-11-04
Jr B William Harrison, Director, 2009-11-04
F Steven Goldstone, Director, 2009-11-04
H Thomas Glocer, Director, 2009-11-04
R Thomas Cech, Director, 2009-11-04
A Leslie Brun, Director, 2009-11-04
G Margaret Mcglynn, Officer, 2009-04-27

Show All Insiders (27)

Insider Trading: Purchases See All

Insider	Price	Amount	Total Value	Remaining Holdings	Date	Form 4
Kelley Director	$33.22	550	$18,268.75	750	2006-01-18	Filing
Kelley Director	$45.65	200	$9,130.56	200	2002-09-24	Filing

News See All

Merck & Co., Inc. (MRK)'s CEO Thinks He's Got $50 Billion Of New Drugs, Says Jim Cramer

Merck & Co., Inc. (NYSE:MRK) is one of the largest pharmaceutical companies in the world. The firm has benefited from its KEYTRUDA cancer drug over the past couple of years. However, Merck & Co., Inc.

Keep Reading →

July 12th, 2025 - News

14 Stocks Jim Cramer Discussed As He Talked About Record Bitcoin Price

In a recent appearance on CNBC's Squawk on the Street, Jim Cramer discussed the recent Bitcoin price jumps.

Keep Reading →

July 11th, 2025 - News

Merck Acquires Verona Pharma for $10B to Support Portfolio with COPD Drug Ohtuvayre Ahead of Keytruda Patent Expiration

Merck & Co. Inc. (NYSE:MRK) is one of the most undervalued NYSE stocks to buy now. On July 9, Merck announced its acquisition of UK-based Verona Pharma for ~$10 billion.

Keep Reading →

July 10th, 2025 - News

UBS Affirms Merck & Co’s (MRK) ‘Buy’ Rating on HPV Vaccine Prospects

Merck & Co., Inc. (NYSE:MRK) is one of the 10 best defensive stocks to buy in a volatile market. On July 2, UBS reiterated a ‘Buy’ rating on the stock and a $105 price target.

Keep Reading →

July 9th, 2025 - News

10 Best Defensive Stocks to Buy in a Volatile Market

Investor positioning in defensive stock is at its lowest level it has ever been since 2000.

Keep Reading →

July 9th, 2025 - Hedge Funds News

FDA Grants Priority Review for Merck & Co's (MRK) WINREVAIR

Merck & Co., Inc. (NYSE:MRK) is one of the 10 Best Dip Stocks to Buy According to Billionaires. On July 2, Merck & Co., Inc.

Keep Reading →

July 6th, 2025 - News

Merck & Co (MRK) Announces the Approval of ENFLONSIA

Merck & Co., Inc. (NYSE:MRK) is one of the 11 Best 52-Week Low Stocks to Buy Right Now. On June 26, Merck & Co., Inc.

Keep Reading →

July 6th, 2025 - News

TD Cowen Maintains Hold Rating on Merck After Enflonsia Vaccine Update

Merck & Co., Inc. (NYSE:MRK) ranks among the best set-it-and-forget-it stocks to buy. On June 27, TD Cowen maintained its Hold rating and $100 price target on Merck & Co., Inc.

Keep Reading →

July 4th, 2025 - News

11 Best 52-Week Low Stocks to Buy Right Now

On July 2, Tom Lee, Fundstrat's Head of Research and CIO, joined CNBC Television to discuss market conditions. He noted that the investors remain skeptical despite strong market gains.

Keep Reading →

July 3rd, 2025 - Hedge Funds News